Avenue Therapeutics ATXI

Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The company concentrates its efforts on advancing product candidates through clinical development and regulatory pathways toward potential approval and market launch. Its core activities involve securing licensing agreements for innovative compounds, conducting preclinical and clinical studies, and pursuing strategic partnerships or financing to support progression of its pipeline.

Avenue Therapeutics, Inc. generates revenue primarily through potential future sales of its product candidates upon regulatory approval and commercialization. The company does not currently have any products generating revenue as all candidates remain in development or have been divested. Revenue generation is anticipated from intravenous tramadol for postoperative acute pain and ATX-04 for Pompe disease as an adjunct to enzyme replacement therapy, contingent on successful clinical outcomes and FDA approval. The company may also receive milestone payments and royalties from licensing or partnership agreements, such as those related to Baergic or future collaborations.

The company operates through the following segments:

• Intravenous Tramadol: This segment focuses on the development of IV tramadol, a schedule IV opioid for the treatment of post-operative acute pain. Avenue Therapeutics, Inc. holds an exclusive license with Revogenex to develop and commercialize IV tramadol in the United States. The product has undergone multiple Phase 3 clinical trials demonstrating efficacy and safety in postoperative pain models, including bunionectomy and abdominoplasty surgeries.
• ATX-04: This segment centers on the development of ATX-04, a selective β2-adrenergic agonist (clenbuterol) for the treatment of lysosomal storage diseases, with an initial focus on Pompe disease. The company entered into an exclusive license agreement with Duke University in February 2026 for patents and know-how related to clenbuterol. Preclinical and clinical data from a 52-week Phase I/II study in Pompe disease patients showed improvements in six-minute walk distance, respiratory muscle strength, and reduction in muscle glycogen burden.
• BAER-101 (prior to divestment): This segment previously involved the development of BAER-101, a novel α2/3–subtype-selective GABA A positive allosteric modulator for epilepsy and panic disorders. Through its majority-owned subsidiary Baergic Bio, Inc., Avenue Therapeutics, Inc. advanced BAER-101 until the sale of Baergic to Axsome Therapeutics, Inc. on November 5, 2025. BAER-101 was originally licensed from AstraZeneca AB and is being developed by Axsome as AXS-17 for epilepsy.

Avenue Therapeutics, Inc. operates in the highly competitive specialty pharmaceutical industry, where it faces challenges from larger biotechnology and pharmaceutical companies with greater financial and operational resources. The company differentiates itself through its focused pipeline in neurologic diseases, strategic licensing of novel compounds like ATX-04 and IV tramadol, and pursuit of regulatory approval via the 505(b)(2) pathway. Its competitive advantages include ownership of key patents related to IV tramadol administration methods and exclusive global rights to ATX-04 for lysosomal storage diseases, which provide barriers to entry and potential for market differentiation upon approval.

The company serves healthcare providers and patients suffering from neurologic and acute pain conditions. Specific customer types include hospitals, outpatient surgical centers, physicians managing postoperative pain, and neurologists treating rare diseases such as Pompe disease and epilepsy. While no specific customer names are disclosed in the filing, the target market encompasses institutional and individual providers involved in acute care and neurology treatment settings.